MK3207 for Treatment of Acute Migraines (3207-005)

NCT00712725 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

676

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: MK3207- 2.5 mg
DRUG: MK3207- 5 mg
DRUG: MK3207- 10 mg
DRUG: MK3207- 20 mg
DRUG: MK3207- 50 mg
DRUG: MK3207- 100 mg
DRUG: Comparator: placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC